ClinicalTrials.gov
ClinicalTrials.gov Menu

Contrast (Sonazoid)-Enhanced US as a Screening Tool for Hepatocellular Carcinoma in Cirrhosis: An Exploratory Cross-sectional Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02188901
Recruitment Status : Completed
First Posted : July 14, 2014
Last Update Posted : April 26, 2018
Sponsor:
Collaborator:
GE Healthcare
Information provided by (Responsible Party):
Yonsei University

Brief Summary:
B-mode ultrasonography (B-US), a standard method of surveillance of hepatocellular carcinoma (HCC), has a fair sensitivity of 63% in detecting early stage HCC. Sonazoid, a contrast agent for ultrasonography, has reported to have superior sensitivity in detecting focal liver lesion since it has ability of Kupffer phase imaging as well as vascular phase imaging. So our aim is to compare the detection rate of early stage HCC and false referral rate of HCC between B-mode US and Sonazoid-enhanced ultrasonography (S-US) within the same prospective data group. Our hypothesis is that S-US has superior detection rate of early stage HCC (5%) than that of B-mode US (3%).

Condition or disease Intervention/treatment Phase
Hepatocellular Carcinoma (HCC) Other: Sonazoid-enhanced ultrasonography Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 523 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Screening
Official Title: Contrast (Sonazoid)-Enhanced US as a Screening Tool for Hepatocellular Carcinoma in Cirrhosis: An Exploratory Cross-sectional Study
Actual Study Start Date : October 15, 2014
Actual Primary Completion Date : August 3, 2016
Actual Study Completion Date : August 3, 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ultrasound
U.S. FDA Resources

Arm Intervention/treatment
single arm Other: Sonazoid-enhanced ultrasonography
Sonazoid (perflubutane) [GE healthcare]
Other Name: 0.015ml/kg of suspension containing 16μl of perflubutane microbubble and 2ml of diluent, IV (in the vein) on day 1



Primary Outcome Measures :
  1. Detection rate of early stage HCC [ Time Frame: 30±30 days after S-US if there is one or more suspicious HCC detected on S-US, or 180±30 days after S-US if there is no suspicious HCC detected on S-US ]
    Detection rate of early-stage HCC = (Number of confirmed early-stage HCC detected by a given modality) / (Total number of patients enrolled) x100

  2. False referral rate of HCC [ Time Frame: 30±30 days after S-US if there is one or more suspicious HCC detected on S-US, or 180±30 days after S-US if there is no suspicious HCC detected on S-US ]
    False referral rate of HCC =



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patient 20 years old or older,
  2. Patient at high risk of HCC and is supposed to take ultrasonography,
  3. Patient who has no suspicious HCC on previous examinations or patient who undergoes the first surveillance,
  4. Patient who has liver cirrhosis proven by one of the following methods-liver biopsy (METAVIR score 4), identification of esophageal or gastric varix by endoscopically or radiologically, surface nodularity on ultrasonography, CT or MRI, platelet count less than 100,000/mm3, serum albumin less than 3.5 g/dl, or prothrombin time higher than 1.3 INR,
  5. Patient without contraindication for sonazoid,
  6. Patient willing to sign the informed consent

Exclusion Criteria:

  1. Patient on pregnancy or breast feeding,
  2. Patient with allergy to egg,
  3. Patient with left-to-right shunt, respiratory insufficiency, or severe pulmonary hypertension,
  4. Patient with history of HCC,
  5. Patient with history of malignancy other than HCC -

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02188901


Locations
Korea, Republic of
Severance Hospital, Yonsei University College of Medicine
Seoul, Korea, Republic of, 120-752
Sponsors and Collaborators
Yonsei University
GE Healthcare

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Yonsei University
ClinicalTrials.gov Identifier: NCT02188901     History of Changes
Other Study ID Numbers: 4-2014-0337
First Posted: July 14, 2014    Key Record Dates
Last Update Posted: April 26, 2018
Last Verified: April 2018

Keywords provided by Yonsei University:
HCC
Sonazoid
Ultrasonography
Screening

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases